March 2005 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
66 citations
,
January 2010 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.
54 citations
,
May 2019 in “Multiple Sclerosis and Related Disorders” Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.